Menu

Alpha Stories

Childhood liver disease studies enrolling patients; some travel funds available to eligible families

Tuesday, June 8, 2010
The Childhood Liver Disease Research and Education Network (ChiLDREN) is enrolling children now for vital research studies on cholestatic liver diseases of children. In cholestatic liver disease, the flow of bile from the liver into the digestive tract is obstructed or little or no bile is secreted. Alpha-1 Antitrypsin Deficiency is an example of a cholestatic liver disease. CHILDREN is a...
Divider

Grifols, Talecris press release on planned acquisition

Monday, June 7, 2010
PR Newswire BARCELONA, Spain and RESEARCH TRIANGLE PARK, NC—Grifols a global healthcare company and leading producer of plasma protein therapies, and Talecris, a US-based biotherapeutics products company, today announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares having an...
Divider

Spanish company Grifols to acquire Talecris for $3.4 billion

Monday, June 7, 2010
Reuters Spain’s Grifols has agreed to buy US-based Talecris Biotherapeutics, which makes plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products. Talecris is the manufacturer of Prolastin, the augmentation therapy for Alpha-1 Antitrypsin Deficiency. Grifols also manufactures an augmentation therapy, distributed in some European...
Divider

Marta Strock dies; one of first AlphaNet coordinators

Monday, June 7, 2010
Marta Strock was one of the first AlphaNet coordinators, and proud of it. “As an AlphaNet coordinator,” she told a magazine writer in 2004, “I have the opportunity to bring a wealth of knowledge about our disease to many Alphas around the country. Knowledge that helps, support, and builds hope for a patient population that just a few years ago had none.” Strock became...
Divider

Anti-seizure drug improves liver disease in Alpha-1 mice

Friday, June 4, 2010
A note from Robert A. Sandhaus, MD, PhD, clinical director of the Alpha-1 Foundation and medical director of AlphaNet: In the interest of presenting the latest information to our Alpha-1 community, the following press release has been posted here. We would like to point out some issues in considering the information presented in this release. First, this is not a scientific article,...
Divider

Whom to test, whom to treat, for Alpha-1?

Friday, June 4, 2010
An examination of the current issues in testing and treating for Alpha-1 has been published by Robert A. Sandhaus, MD, PhD, in the journal Seminars in Respiratory and Critical Care Medicine. Sandhaus is clinical director of the Alpha-1 Foundation, medical director of AlphaNet, and director of the Alpha-1 program at National Jewish Health, Denver. The article, titled, “Alpha -1...
Divider
First9101112131415161718